Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01543-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ava J Dorazio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cephalosporins, beta-Lactamase Inhibitors, Pseudomonas aeruginosa, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane–tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new ampC mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane–tazobactam, ceftolozane–avibactam (AVI), ceftolozane–relebactam (REL), and ceftolozane–durlobactam (DUR), respectively. Enhanced ceftolozane–durlobactam activity was evident in specific ampC mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Center for Innovative Antimicrobial Therapy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Ava J Dorazio, Kevin M Squires, Daria Van Tyne, Ryan K Shields
Förderung
- NIAID NIH HHS
Zitieren
APA
Dorazio, A. J., Kline, E. G., Squires, K. M., Pogue, J. M., Van Tyne, D., & Shields, R. K. (2025). Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01543-24
Vancouver
Dorazio AJ, Kline EG, Squires KM, Pogue JM, Van Tyne D, Shields RK. Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01543-24
BibTeX
@article{Dorazio2025,
author = {Dorazio, Ava J and Kline, Ellen G and Squires, Kevin M and Pogue, Jason M and Van Tyne, Daria and Shields, Ryan K},
title = {Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01543-24}
}
EUVIMED